Data from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

MLA

David S. Hong, et al. Data from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses. Apr. 2023. EBSCOhost, https://doi.org/10.1158/2326-6066.c.6550050.v1.

APA

David S. Hong, Ritsuko Komaki, Stephen Hahn, Daniel R. Gomez, Clark Anderson, Kelvin Wang, Maria E. Cabanillas, Ramona Dadu, Sherif G. Shaaban, Uma Raju, Vivek Verma, Adi Diab, James P. Allison, Padmanee Sharma, Quynh Nguyen, Erminia Massarelli, Maria Angelica Cortez, Hari Menon, Hampartsoum B. Barsoumian, … James W. Welsh. (2023). Data from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses. https://doi.org/10.1158/2326-6066.c.6550050.v1

Chicago

David S. Hong, Ritsuko Komaki, Stephen Hahn, Daniel R. Gomez, Clark Anderson, Kelvin Wang, Maria E. Cabanillas, et al. 2023. “Data from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses,” April. doi:10.1158/2326-6066.c.6550050.v1.